Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Indian Journal of Gastroenterology
Published in: Indian Journal of Gastroenterology 3/2010

01-05-2010 | Letters

Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C

Authors: Ajit Sood, Vandana Midha, Jaswinder S. Sandhu, Neena Sood, Amarjit Kaur, Rasham Mittal, Sandeep Puri

Published in: Indian Journal of Gastroenterology | Issue 3/2010

Login to get access

Excerpt

Interferon therapy for hepatitis C can result in renal complications as interstitial nephritis, minimal change disease and immune complex glomerulonephritis [1]. We present the case of a 42-year old man infected with chronic hepatitis C who developed focal and segmental glomerulosclerosis (FSGS) after treatment with pegylated interferon alfa 2a and ribavirin. …
Literature
1.
Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis. 2003;42:631–57.CrossRefPubMed
2.
Willson RA. Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. J Clin Gastoenterol. 2002;35:89–92.CrossRef
3.
Quesada JR, Talpaz M, Rios A, Kurzrock R, Gutterman JU. Clinical toxicity of interferons in cancer patients: a review. J Clin Oncol. 1986;4:234–43.PubMed
4.
Jones GJ, Itri LM. Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients. Cancer. 1986;57(8 Suppl):1709–715.CrossRefPubMed
5.
Coroneos E, Petrusevska G, Varghese F, Truong LD. Focal segmental glomerulosclerosis with acute renal failure associated with alpha-interferon therapy. Am J Kidney Dis. 1996;28:888–92.CrossRefPubMed
6.
Nassar GM, Pedro P, Remmers RE, Mohanty LB, Smith W. Reversible renal failure in a patient with the hypereosinophilia syndrome during therapy with alpha interferon. Am J Kidney Dis. 1998;31:121–6.CrossRefPubMed
7.
Stein DF, Ahmed A, Sunkhara V, Khalbuss W. Collapsing focal segmental glomerulosclerosis with recovery of renal function: an uncommon complication of interferon therapy for hepatitis C. Dig Dis Sci. 2001;46:530–35.CrossRefPubMed
8.
Bremer CT, Lastrapes A, Alper Jr AB, Mudad R. Interferon-alpha-induced focal segmental glomerulosclerosis in chronic myelogenous leukemia: a case report and review of the literature. Am J Clin Oncol. 2003;26:262–4.CrossRefPubMed
9.
Alves Couto C, Costa Faria L, Dias Ribeiro D, de Paula Farah K, de Melo Couto OF, de Abreu Farrari TC. Life-threatening thrombocytopenia and nephrotic syndrome due to focal segmental glomerulosclerosis associated with peglated intereron alpha-2b and ribavirin treatment for hepatitis C. Liver Int. 2006;26:1294–7.CrossRefPubMed
10.
Tovar JL, Buti M, Segarra A, Majo J, Esteban R. De novo nephrotic syndrome following pegylated interferon alfa 2b/ ribavirin therapy for chronic hepatitis C infection. Int Urol Nephrol. 2008;40:539–41.CrossRefPubMed
Metadata
Title
Nephrotic syndrome with pegylated interferon alfa 2a and ribavirin for a patient with chronic hepatitis C
Authors
Ajit Sood
Vandana Midha
Jaswinder S. Sandhu
Neena Sood
Amarjit Kaur
Rasham Mittal
Sandeep Puri
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Indian Journal of Gastroenterology / Issue 3/2010
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-010-0012-5

Other articles of this Issue 3/2010

Indian Journal of Gastroenterology 3/2010 Go to the issue

Image

Development of multiple peribiliary cysts following acute alcoholic hepatitis

Original Article

Characterization of clarithromycin resistance in isolates of Helicobacter pylori from the UAE

Short Report

Celiac axis compression by median arcuate ligament on computed tomography among asymptomatic persons

Image

Endoscopic ultrasound in biliary fasciolosis

Letters

Does plasma resistin level have a role in predicting inflammatory bowel disease activity?

Review

The enigma of Helicobacter pylori infection and gastric cancer
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits